Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: Results from the ATLAS trial

European Heart Journal

Volumn 21, Issue 23, 2000, Pages 1967-1978

  Rydén, Lars ^a,h   Armstrong, P W ^b   Cleland, J G F ^c   Horowitz, J D ^d   Massie, B M ^e   Packer, M ^f   Poole Wilson, P A ^g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF HULL   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACE inhibitor; Diabetes mellitus; Heart failure; Hospitalization; Lisinopril; Mortality

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; NITRIC ACID DERIVATIVE; POTASSIUM; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPONATREMIA; HYPOTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0033694573     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2311     Document Type: Article

References (18)

1. Effects of enalapril on mortality in severe congestive heart failure
2. Effect of vasodilator therapy on mortality in chronic congestive heart failure
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
4. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
5. ACE inhibitors for heart failure: A question of dose
6. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?
7. Comparative effects of low doses and high doses of the angiotensin converting-enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
8. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
9. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms
10. Drug-induced orthostatic hypotension in the elderly: Avoiding its onset
11. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors
12. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure
13. Preservation of a glomerular filtration rate in human heart failure by activation of the rennin-angiotensin system
14. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group
15. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial
16. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study
17. Randomised placebo-controlled study of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
18. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes